Over the last decade, the states of Pennsylvania and Delaware have experienced a sharp increase in prescription opioid abuse and related overdoses, many resulting in death. In an effort to identify potential sources and demonstrate the availability of these abused pharmaceuticals, the DEA Philadelphia Division Intelligence Program conducted a review and analysis of oxycodone, hydrocodone, and buprenorphine orders by registrants in Pennsylvania and Delaware for the years 2010-2013.
